Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Mahnum Shahzad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Genetic Therapy, Drug Approval, Cell- and Tissue-Based Therapy. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The development and use of cell and gene therapies (CGTs) are rapidly expanding and challenge traditional regulatory paradigms. With growing clinical use and high costs, rigorous evaluation of regulatory oversight by the US Food and Drug Administration (FDA) is increasingly important. We characterized premarketing evidence and postmarketing requirements and commitments for all 38 CGTs approved by the FDA through December 31, 2025. Most therapies used special designations and expedited pathways (86.8% had an orphan designation; 92.1% used an expedited pathway). The mean number of pivotal studies required for CGT approval was 1.6 (SD 1.7), with 73.7% approved based on a single study, and 44.7% relying solely on studies with surrogate endpoints. Reliance on postmarketing evidence generation was common, with 73.4% of products approved with at least one postmarketing requirement or commitment, totaling 52 studies. However, only 17.9% of CGTs had a postmarketing study that included a primary clinical efficacy endpoint, and most studies remain ongoing. These findings suggest that current regulatory approaches prioritize timely access but often rely on limited premarket data and postmarketing studies that infrequently assess clinical efficacy outcomes. Ensuring that requirements for preapproval trials and postmarketing studies are adequate and appropriately calibrated to the level of uncertainty and benefit–risk profile of individual CGTs may better support the goal of providing patients with timely, innovative, and transformative treatments that have the greatest potential to advance disease treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA.
- Cellular Immunotherapy Program, Mass General Cancer Center, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
- Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Mahnum Shahzad, Magdi Elsallab, Maximilian Siebert, Florence T Bourgeois
Zitieren
APA
Shahzad, M., Elsallab, M., Siebert, M., & Bourgeois, F. T. (2026). Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70396
Vancouver
Shahzad M, Elsallab M, Siebert M, Bourgeois FT. Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70396
BibTeX
@article{Shahzad2026,
author = {Shahzad, Mahnum and Elsallab, Magdi and Siebert, Maximilian and Bourgeois, Florence T},
title = {Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70396}
}
EUVIMED